Merck receives green light in US for SpringWorks buy
Pharmaceutical giant Merck’s proposed $3.9 billion acquisition of cancer and rare disease drugmaker SpringWorks Therapeutics has received clearance from the US antitrust authorities. The waiting period under the Hart-Scott-Rodino act expired...To view the full article, register now.
Already a subscriber? Click here to view full article